vimarsana.com

Latest Breaking News On - Ibrahimt aldoss - Page 1 : vimarsana.com

Dr Aldoss on the Use of Revumenib in KMT2A-Rearranged Acute Leukemia

Ibrahim T. Aldoss, MD, discusses the use of revumenib monotherapy in patients with relapsed/refractory acute leukemia harboring KMT2A rearrangements.

Ibrahimt aldossDepartment of hematology hematopoietic cell transplantationDivision of leukemiaHematopoietic cell transplantationHematologic oncologyOnclive tvCity of hope

ASH recap: Transformative advance in sickle cell disease, breakthrough in AML and ALL

ASH recap: Transformative advance in sickle cell disease, breakthrough in AML and ALL
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Julie kanterJamesr berensonEmicizumab hemlibraIbrahimt aldossBymark leiserMikkaela sekeresAlexis thompsonSaadz usmaniCynthiae dunbarJoshua brodyMariaj fernandez turizoMindy valcarcelSyndax pharmaceuticalsIncyte syndax pharmaceuticalsBluebird bioPeter hillmen

Pivotal Results Show Revumenib Holds Promise for Patients With KMT2Ar Acute Leukemia

In AUGMENT-101, patients with R/R KMT2Ar acute leukemia had high overall response rates; despite being heavily pretreated, 40% were able to proceed to transplant and the KMT2Ar cohort was stopped early.

United statesSan diegoIbrahimt aldossAmerican society of hematology annual meetingCity of hope national medical centerHope national medical centerAmerican societyHematology annual meetingAmerican journalManaged careNew drug application

Revumenib represents a significant breakthrough for treatment of acute leukemia

Revumenib represents a significant breakthrough for treatment of acute leukemia
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesIbrahimt aldossSyndax pharmaceuticals

Dr Ibrahim Aldoss on the Need for Targeted Therapy for KMT2Ar Acute Leukemias

Ibrahim T. Aldoss, MD, of City of Hope Comprehensive Cancer Center, discusses the potential of revumenib in KMT2A-rearranged (KMT2Ar) acute leukemias, with pivotal results presented at the 65th Annual American Society of Hematology Annual Meeting and Exposition this week.

United statesIbrahimt aldossAmerican society of hematology annual meetingCity of hope national medical centerHope national medical centerAnnual american societyHematology annual meetingMash 2023

vimarsana © 2020. All Rights Reserved.